Valuation: Avalo Therapeutics, Inc.

Market Cap 97Cr 84Cr 78Cr 72Cr 135.08Cr 9.22TCr 137.23Cr 918.52Cr 360.52Cr 4.62TCr 363.95Cr 355.98Cr 15TCr P/E 2026 *
-6.23x
P/E 2027 * -6.04x
Enterprise Value 55Cr 47Cr 44Cr 41Cr 76Cr 5.21TCr 78Cr 518.86Cr 203.65Cr 2.61TCr 205.59Cr 201.09Cr 8.63TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.95%
Yield 2026 *
0.06%
Yield 2027 * -
1 day-2.03%
1 week+0.38%
Current month+0.38%
1 month-4.83%
3 months-19.90%
6 months+29.11%
Current year+0.88%
1 week 17.64
Extreme 17.64
19.84
1 month 17.54
Extreme 17.54
20.45
Current year 12.51
Extreme 12.51
24.27
1 year 8.29
Extreme 8.29
24.27
3 years 3.39
Extreme 3.39
71.04
5 years 3.39
Extreme 3.39
9,331.13
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 14/02/2022
Director of Finance/CFO 42 14/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 08/08/2022
Director/Board Member 78 12/10/2020
Director/Board Member 55 28/03/2024
Date Insider Type Main position Quantity % Market Cap.
27/07/26 Fiscal year

Chief Technology Officer

3,000 0.0057%
30/06/26 Free

Director

1,080 0.0020%
30/06/26 Fiscal year

Chief Technology Officer

13,962 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
-2.03%+0.38%+119.40%-52.23% 97Cr
+8.49%+20.55%+69.74%+109.30% 6.81TCr
+1.25%+2.44%+32.55%+72.63% 5.52TCr
-1.09%+32.96%+19.95%+499.45% 2.86TCr
+2.72%+3.41%-15.88%-4.90% 2.35TCr
+10.83%+18.38%+52.76%+4.58% 2.4TCr
+6.50%+7.56%+38.20%-21.33% 1.84TCr
-3.88%+16.98%+199.30%+354.30% 1.58TCr
+6.20%+11.51%+34.94%+681.88% 1.64TCr
+3.58%+1.96%+44.61%+167.01% 1.34TCr
Average +3.26%+10.55%+59.56%+181.07% 2.65TCr
Weighted average by Cap. +4.33%+13.05%+49.74%+167.68%

Financials

2026 *2027 *
Net sales - -
Net income -10Cr -8.82Cr -8.24Cr -7.55Cr -14Cr -970.3Cr -14Cr -97Cr -38Cr -486.34Cr -38Cr -37Cr -1.61TCr -13Cr -11Cr -10Cr -9.44Cr -18Cr -1.21TCr -18Cr -120.75Cr -47Cr -607.79Cr -48Cr -47Cr -2.01TCr
Net Debt -42Cr -36Cr -34Cr -31Cr -59Cr -4.01TCr -60Cr -399.66Cr -156.86Cr -2.01TCr -158.36Cr -154.89Cr -6.65TCr -31Cr -27Cr -25Cr -23Cr -43Cr -2.93TCr -44Cr -291.76Cr -114.51Cr -1.47TCr -115.6Cr -113.07Cr -4.85TCr
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.
Employees
33
Date Price Change Volume
07/26/07 $18.32 -2.03% 7,30,255
06/26/06 $18.70 -0.74% 5,96,213
05/26/05 $18.84 +1.67% 7,34,514
04/26/04 $18.53 +2.66% 11,57,469
03/26/03 $18.05 -1.10% 5,72,280
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
18.32USD
Average target price
44.15USD
Spread / Average Target
+141.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVTX Stock